Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
8 hedge funds and large institutions have $9.07M invested in Celyad Oncology SA American Depositary Shares in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
20% less capital invested
Capital invested by funds: $11.4M → $9.07M (-$2.31M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$30.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$57K |
| 2 |
Morgan Stanley
New York
|
-$1.84K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.84K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIG
1
Fortress Investment Group
New York
| $8.97M | – | – | – |
|
|
2
Morgan Stanley
New York
| $26K | -$1.84K | -1,000 | -5% |
|
|
3
Citadel Advisors
Miami,
Florida
| $22K | +$30.6K | +16,654 | New |
|
|
4
Wells Fargo
San Francisco,
California
| $18K | -$1.84K | -1,000 | -7% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $16K | +$21.4K | +11,602 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $12K | +$8.57K | +4,658 | +115% |
|
7
National Bank of Canada
Montreal,
Quebec, Canada
| $5K | – | – | – |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $2K | – | – | – |
|
|
HF
9
HRT Financial
New York
| – | -$57K | -33,288 | Closed |
|
|
CS
10
Credit Suisse
Zurich,
Switzerland
| – | -$1K | -838 | Closed |
|
CYAD Hedge Fund Activity: Q3 2022 in Review
8 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q3 2022, worth a combined $9.07M — down 20% from $11.4M a quarter earlier.
Fund positioning in CYAD was balanced in Q3 2022: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $30.6K. The largest seller was HRT Financial, exiting entirely with an estimated $57K sold.
- 8 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $9.07M of Celyad Oncology SA American Depositary Shares stock for Q3 2022, down 20% quarter-over-quarter.
- 2 funds opened new Celyad Oncology SA American Depositary Shares positions in Q3 2022 and 2 closed out, a net change of 0 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q3 2022 was Citadel Advisors, an estimated $30.6K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q3 2022 was HRT Financial, an estimated $57K sold.
Based on aggregated 13F filings for Q3 2022.